|
||
© The Rockefeller University Press,
0021-9525/1999//1255 $5.00
The Journal of Cell Biology, Volume 146, Number 6,
, 1999 1255-1264
Original Article |
Regulation of P21cip1 Expression by Growth Factors and the Extracellular Matrix Reveals a Role for Transient ERK Activity in G1 Phase
rka{at}pharm.med.upenn.edu
We have examined the regulation of p21cip1 by soluble mitogens and cell anchorage as well as the relationship between the expression of p21cip1 and activation of the ERK subfamily of MAP kinases. We find that p21cip1 expression in G1 phase can be divided into two discrete phases: an initial induction that requires growth factors and the activation of ERK, and then a subsequent decline that is enhanced by cell anchorage in an ERK-independent manner. In contrast to the induction of cyclin D1, the induction of p21cip1 is mediated by transient ERK activity. Comparative studies with wild-type and p21cip1-null fibroblasts indicate that adhesion-dependent regulation of p21cip1 is important for proper control of cyclin E–cdk2 activity. These data lead to a model in which mitogens and anchorage act in a parallel fashion to regulate G1 phase expression of p21cip1. They also show that (a) growth factors and growth factor/extracellular matrix cooperation can have different roles in regulating G1 phase ERK activity and (b) both transient and sustained ERK signals have functionally significant roles in controlling cell cycle progression through G1 phase.
Key Words: cell cycle adhesion ECM MAP kinase cdk inhibitors
© 1999 The Rockefeller University Press
THE majority of cells in the adult are thought to be in a resting quiescent state. When suitable extracellular cues are present, e.g., during a response to injury, cells leave this quiescent (G0) state and enter the G1 phase of the cell cycle. For most cell types, the extracellular cues that mediate progression through G1 phase can be divided into two general groups: soluble mitogenic growth factors and the extracellular matrix (ECM)1 (reviewed in Assoian 1997). The signaling potential of soluble mitogens and the ECM results from their ability to bind to and cluster specific cell surface receptors, typically receptor tyrosine kinases (RTKs) and integrins, respectively.
When RTKs and integrins are signaling, cells undergo a series of molecular events involving cyclins, cyclin-dependent kinases (cdks), and cdk inhibitors (CKIs) (reviewed in Hunter and Pines 1994; Sherr 1994; Sherr and Roberts 1995). Two cyclin-cdk activities, cyclin D–cdk4/6 and cyclin E–cdk2, are required for progression of cells through G1 phase. In large part, these enzymes are required because they phosphorylate the retinoblastoma protein (pRb); this event allows for the release of E2F and the induction of E2F-regulated genes such as cyclin A (Weinberg 1995). The induction of cyclin A, with consequent formation of active cyclin A–cdk2 complexes, is thought to reflect entry into S phase of the cell cycle.
In fibroblasts and epithelial cells, mitogens and the ECM are jointly required to induce the expression of cyclin D1 mRNA (Böhmer et al. 1996; Zhu et al. 1996; Day et al. 1997; Radeva et al. 1997; Resnitzky 1997). This effect has been linked to sustained ERK activity and the role of integrin signaling in sustaining ERK activity throughout G1 phase (Weber et al. 1997; Roovers et al. 1999). The translation of cyclin D1 mRNA is also dependent upon cell adhesion (Zhu et al. 1996; Huang et al., 1998). The combined mitogen/anchorage requirement for expression of cyclin D1 explains, in part, why hyperphosphorylation of pRb and expression of cyclin A are also jointly dependent upon exposure of cells to mitogens and an ECM.
In addition to their cooperative effects in the induction of cyclin D1, mitogens and the ECM are also jointly required for activation of cyclin E–cdk2 (reviewed in Assoian 1997). The cyclin E–cdk2 complexes harvested from suspended cells are catalytically inactive when assayed in vitro despite the fact that the cells had been exposed to growth factors. Suspended cells express elevated levels of two CKIs, p21cip1 and p27kip1, and the catalytically inactive cyclin E–cdk2 complexes isolated from suspended cells show increased association of both p21cip1 and p27kip1. Neither CAK activity nor the levels of cyclin E and cdk2 are significantly different in adherent vs. nonadherent cells, so it seems likely that mitogens and anchorage jointly regulate cyclin E–cdk2 activity by controlling the expression of p21cip1 and p27kip1. Changes in p21cip1 expression are often associated with altered transcription of the gene, whereas changes in p27kip1 levels have typically been associated with changes in protein translation or degradation (Hengst and Reed 1996; Sheaff et al. 1997; Montagnoli et al. 1999). Thus, very different mechanisms likely underlie the effects of growth factors and the ECM on p21cip1 and p27kip1 levels.
In this study, we have examined the regulation of p21cip1. p21cip1 is poorly expressed in quiescent cells, it is rapidly induced when cells are stimulated with mitogens, and its expression then declines as cells reach mid-late G1 phase (Li et al. 1994; Macleod et al. 1995; Liu et al. 1996; Bosch et al. 1998). The early G1 phase induction of p21cip1 plays a role in the assembly of cyclin D–cdk4/6 complexes (LaBaer et al. 1997; Cheng et al. 1999), and the mid-late G1 phase decline of p21cip1 correlates with activation of cyclin E–cdk2. p53 is important for induction of the p21cip1 promoter (El-Deiry et al. 1993), but p53-independent mechanisms also induce the p21cip1 gene (Macleod et al. 1995; Zeng et al., 1996). In fact, activation of ERKs has been strongly implicated in the induction of p21cip1 (Liu et al. 1996; Pumiglia and Decker 1997; Auer et al. 1998).
We report here that p21cip1 expression can be divided into two discrete phases: an initial induction that requires mitogens and ERK activity and a subsequent downregulation that is enhanced by cell anchorage and independent of ERK activity. Thus, growth factors and the ECM act in parallel to regulate the expression of p21cip1 during G1 phase. We also report that, in contrast to the regulation of cyclin D1, a transient activation of ERK is sufficient to induce p21cip1.
| Materials and Methods |
|---|
|
|
|---|
To study the consequence of ERK activation in suspended cells, we used NIH-3T3 cells stably transfected with a constitutively active MEK-1 (S218D/S222D) in a tetracycline-repressible expression system (Roovers et al. 1999). The transfectants were maintained at <50% confluence in DME, 10% calf serum, 0.5 mg/ml G418, and 0.4 mg/ml hygromycin. Tetracycline (2 µg/ml) was added daily.
Analysis of p21cip1 Promoter Activity
MEFs (1.5 x 105 in 2 ml DME, 10% FCS) were plated in 35-mm dishes and incubated overnight. The resulting monolayers (
80% confluent) were washed with DME before transient cotransfection with 1 µg of p21cip1 promoter-luciferase plasmid (0-luc; gift of Wafik El-Deiry), 0.1 µg of the renilla luciferase expression plasmid, pRL-SV40 (Promega), and 5 µl lipofectamine (Life Technologies) in a total volume of 1 ml serum-free DME without antibiotics. After a 5-h incubation, 1 ml of 20% FCS-DME was added to each well and the cultures were incubated overnight. 18 h after transfection, the cells were G0-synchronized by 2-d incubation in serum-free DME. After trypsinization, an aliquot of the cells was removed for determination of p21cip1-promoter activity at quiescence; the remainder was resuspended in 10% FCS-DME and then replated in 100-mm dishes (0.5–1 x 105 cells/10 ml) in monolayer and suspension. At selected times, cells were washed, collected, and extracted in 50 µl of Passive Lysis Buffer (Promega) before analysis of firefly luciferase and renilla luciferase activity using the Dual-Luciferase reporter assay system (Promega). p21cip1 promoter activity was normalized to a constant amount of renilla-based luminescence to correct for differences in transfection efficiency.
Other Procedures and Reagents
Northern blotting, immunoprecipitations, and in vitro kinase assays were performed as described (Zhu et al. 1996). Immunoblotting for pRb, cyclins, MEK, and ERKs was performed as described (Zhu and Assoian 1995; Zhu et al. 1996) after fractionation of cell lysates on reducing SDS gels containing 7.5% acrylamide. Immunoblotting for CKIs was performed similarly except that the gels contained 15% acrylamide. The protein concentration of cell lysates destined for immunoblot analysis was determined by Coomassie binding (BioRad Protein Assay), and equal amounts (100 µg for the analysis of cyclins, cdks, and CKIs, and 25 µg for the analysis of MEK* and ERK) were fractionated on SDS gels. Cells destined for immunoblot analysis with anti-ERK or anti-phospho-ERK antibodies were extracted as described (Zhu et al. 1999).
Rabbit polyclonal antiserum against cyclin A was prepared in this laboratory, and the antiserum to p21cip1 was the generous gift of Claudio Schneider (AREA Science Park, Trieste, Italy). All other antisera were purchased: anti-cyclin E (sc-481) and anti-cdk4 (sc-260) from Santa Cruz Biotechnology; anti-cyclin D1 (06-137), and anti-cdk2 (06-505) from Upstate Biotechnology; anti-MEK-1 (M17020), anti-p27kip1 (K25020), and anti-ERK (M12320) from Transduction Laboratories, anti-pRb (100601) from Ciba-Corning; and anti-phospho-ERK (9101S) from New England BioLabs.
| Results |
|---|
|
|
|---|
|
Consistent with studies implicating ERK activation in the induction of p21cip1 (see above), we found that the new generation MEK inhibitor, U0126 (Favata et al. 1998) completely blocked the induction of p21cip1 when quiescent MEFs were treated with purified growth factors (Fig. 2 A). This effect was associated with the inhibition of ERK activation (determined by direct detection of phospho-ERK and ERK2 gel-shift). Treatment with rapamycin (a potent inhibitor of p70S6 kinase; Price et al. 1992) or LY294002 (a specific PI 3-kinase inhibitor; Vlahos et al. 1994) did not inhibit the activation of ERK or the induction of p21cip1 (Fig. 2 A). Thus, activation of the MEK/ERK pathway is necessary for the induction of p21cip1 by growth factors. NIH-3T3 transfectants expressing a constitutively active MEK-1 (MEK*) under control of a tetracycline-repressible promoter (tet-MEK*-3T3 cells) were then used to determine if activation of the MEK/ERK pathway would be sufficient to induce p21cip1. Suspended MEFs were incubated in the presence and absence of tetracycline and a minimal mitogenic stimulus (0.5% serum, which permitted the synthesis of MEK* in the absence of tetracycline). In the presence of tetracycline, 0.5% serum had a small effect on ERK activation (assessed by direct detection of phospho-ERK) and little effect on the expression of p21cip1 (Fig. 2 B; compare G0 to +tet). In the absence of tetracycline, MEK* was induced, resulting in a strong phosphorylation of ERKs and an induction of p21cip1 (Fig. 2 B; compare G0 to –tet). Thus, MEK* is sufficient to induce p21cip1 in the absence of both cell anchorage and a strong mitogenic stimulus. This result supports other studies showing that expression of constitutively active raf results in the induction of p21cip1 (Lloyd et al. 1997; Pumiglia and Decker 1997; Sewing et al. 1997; Woods et al. 1997; Auer et al. 1998; Kerkhoff and Rapp 1998).
|
|
To assess directly the duration of the ERK signal that is required for the induction of p21cip1, we activated ERK by stimulating quiescent MEFs with purified growth factors in defined medium and then treated the cultures with UO126 at 10, 20, and 40 min before collection at 1 h. Immunoblot analysis showed that (a) growth factors induced a complete activation of ERK by 10 min (Fig. 4 A), (b) this effect persisted for at least 60 min (Fig. 4 A), and (c) UO126 rapidly inhibited growth factor–dependent ERK activation (with
50 and 90% inhibition in 10 and 20 min, respectively; Fig. 4 B). Importantly, the induction of p21cip1 was completely blocked when UO126 was added either 10 or 20 min after stimulation with growth factors, but it was easily detected when UO126 was added after 40 min (Fig. 4 C). Considering that the inhibitory effect of UO126 on ERK activation is complete within 20 min, we conclude that an ERK signal of 40–60 min is sufficient to induce p21cip1. The same experimental approach was applied to the analysis of cyclin D1 expression, and the results showed that cyclin D1 was not induced even when UO126 was added 60 min after growth factor stimulation. These data support and extend the results of Fig. 3, directly demonstrating that the ERK signal required for induction of p21cip1 is transient relative to that required for the induction of cyclin D1.
|
30 min under both culture conditions (Fig. 5). We were unable to find antibodies suitable for confirmation of this result by immunoprecipitation of p21cip1 from pulse–chase-labeled cells, but our results with cycloheximide indicate that the turnover of p21cip1 is not strongly affected by cell adhesion to substratum.
|
|
|
Effect of p21cip1 on Anchorage-dependent Cyclin E–cdk2 Activity
Cyclin E–cdk2 activity is not induced when fibroblasts are treated with mitogens in the absence of a substratum, and the lack of kinase activity correlates with an increased expression of p21cip1 and p27kip1 (reviewed in Assoian 1997). To determine if this increased expression of p21cip1 is causally related to the inhibition of cyclin E–cdk2 activity, we asked if cyclin E–cdk2 activity would be anchorage independent in suspended cells lacking p21cip1.
G0-synchronized MEFs derived from wild-type and p21cip1-null mice were mitogen-stimulated in monolayer and suspension before collection and analysis of cyclin E–cdk2 kinase activity in vitro. As expected, the activation of cyclin E–cdk2 was completely blocked when wild-type MEFs were cultured in suspension (Fig. 8). In contrast, cyclin E–cdk2 activity was readily detectable in lysates from suspended p21cip1-null cells, at
50% of the value seen in lysates from the adherent p21cip1-null cells. (Because the p21cip1-null and wild-type MEFs are independent isolates, comparisons of cyclin E–cdk2 activity in lysates of quiescent, adherent, and suspended cells should only be made within each established line.) Note that other established markers of G1 phase cell cycle progression (induction of cyclin D1, complete downregulation of p27kip1, phosphorylation of pRb, and expression of cyclin A) were adhesion dependent in both wild-type and p21cip1-null MEFs, consistent with our previous studies (Zhu et al. 1996). The expression of cyclin E and cdk2 was also similar in the wild-type and p21cip1-null cells. Thus, the cyclin E–cdk2 kinase activity detected in suspended p21cip1-null MEFs can be attributed specifically to the loss of p21cip1. In turn, this result indicates that downregulation of p21cip1 participates in the activation of cyclin E–cdk2. The incomplete rescue of cyclin E–cdk2 activity in suspended p21cip1-null MEFs supports previous studies by us and others (Fang et al. 1996; Schulze et al. 1996; Zhu et al. 1996) which indicate that adhesion-dependent downregulation of p27kip1 also contributes to the adhesion dependency of cyclin E–cdk2 activity.
|
| Discussion |
|---|
|
|
|---|
Transient Activation of ERKs Induces p21cip1 in G1 Phase
Our results with pharmacologic inhibitors and conditional expression of constitutively active MEK show that the activation of ERKs plays a major role in the induction of p21cip1 by growth factors. This effect probably contributes to the assembly of cyclin D–cdk4/6 complexes (Cheng et al. 1999). Indeed, a p21cip1-mediated assembly of cyclin-cdk complexes could explain the results of Cheng et al. 1998, which indicate that activation of the MEK/ERK pathway is sufficient to override the mitogen requirement for assembly of cyclin D–cdk4/6 complexes. In contrast to the induction of cyclin D1, growth factors can induce p21cip1 whether or not cells are attached to a substratum. This anchorage independency of p21cip1 induction reflects the fact that a transient activation of ERK is sufficient to induce p21cip1. In our studies and some others (this report; Zhu and Assoian 1995; Renshaw et al. 1997; Clark et al., 1998), transient ERK activation occurred in response to growth factors and in the absence of cell adhesion. However, others have also reported that growth factors poorly activate ERK when cells are cultured in the absence of a substratum (e.g., Miyamoto et al. 1996; Lin et al. 1997; Renshaw et al. 1997; Short et al. 1998; Aplin and Juliano 1999). The different results may reflect how long cells are kept in suspension before growth factor stimulation (Renshaw et al. 1997) or whether the cells have received a sufficiently strong mitogenic stimulus as described in Fig. 3 C.
Others have shown that the induction of p21cip1 requires a stronger ERK signal than does the induction of cyclin D1 (Sewing et al. 1997; Woods et al. 1997). In agreement with these studies, our results do show that the persistent ERK signal seen throughout G1 phase and associated with cyclin D1 expression is not as strong as the transient, early G1 ERK signal associated with the induction of p21cip1. Some studies also suggest that sustained ERK activity mediates the induction of p21cip1 (Pumiglia and Decker 1997; Auer et al. 1998), while our results show that a transient activation is sufficient. A likely explanation for these different results is that most of the studies by others have relied on overexpression of activated rafs, and the nature of this experimental approach precludes an analysis of effects mediated by transient ERK activity.
Adhesion-dependent Downregulation of p21cip1 and Its Independence from MAP Kinase
Our data also suggest that the effect of cell anchorage on mid-late G1 repression of p21cip1 gene expression is important for cell cycle progression. We and others have previously reported that p21cip1 and p27kip1 levels increase when fibroblasts are cultured with mitogens in suspension, and this increase in CKIs is associated with inactivity of the cyclin E–cdk2 complex. Cyclin E–cdk2 is partially anchorage independent in cells lacking p21cip1, implying that downregulation of p21cip1 in normal cells contributes to the activation of cyclin E–cdk2. The increased expression of p21cip1 in suspended cells has typically been interpreted as an induction, but the results shown here indicate that impaired downregulation of p21cip1 is the proper explanation.
Brugarolas et al. 1998 have also examined the effect of p21cip1 on the anchorage dependency of cyclin E–cdk2 activity. Consistent with our results, they found that cyclin E–cdk2 activity in suspended pRb/p21cip1-null MEFs was higher than that in wild-type MEFs. However, we found that cyclin E–cdk2 activity in suspended p21cip1-null MEFs was half of that seen in the adherent p21cip1-null MEFs while they reported that the cyclin E–cdk2 activity of suspended pRb/p21cip1-null cells was only 20% of that observed with adherent pRb/p21cip1-null cells. The difference between their results and ours may reflect the fact that our analysis was performed with cells in the first G1 phase while their studies used cells incubated in suspension for three days before analysis. The cell cycle blocks in their system and ours may be of a different nature and not directly comparable. Moreover, we can not exclude the possibility that the pRb-null phenotype of the MEFs used by Brugarolas et al. 1998 may also contribute to the different results.
There is precedent for negative regulation of p21cip1 protein by rho (Olson et al. 1998). Negative regulatory motifs have also been mapped to the 3' untranslated region in the p21cip1 mRNA (Rishi et al. 1997). Downregulation of the p21cip1 promoter may also be specific to positional cues in the cell cycle because the p21cip1 promoter is downregulated in mid-late G1; cells treated with mitogens in suspension fail to reach mid-late G1 (Schwartz et al. 1991; Böhmer et al. 1996). The effect of cell anchorage on these different modes of regulation remains to be elucidated. Importantly, the downregulation of p21cip1 observed in response to cell adhesion is independent of ERK activity and can even occur in the presence of a sustained ERK signal. This allows the cell to fully downregulate p21cip1 expression in the presence of the sustained ERK signal needed for the induction of cyclin D1.
Several laboratories have shown that high-intensity raf signals induce p21cip1 and also result in a p21cip1-dependent cell cycle arrest (Lloyd et al. 1997; Pumiglia and Decker 1997; Sewing et al. 1997; Woods et al. 1997; Auer et al. 1998). As discussed above, the induction of p21cip1 by raf is probably the result of ERK activation and is consistent with our studies. The persistently elevated expression of p21cip1 characteristic of cell cycle arrest in high intensity raf transformants suggests that overexpression of constitutively activated raf can override the normal ERK-independent signaling mechanism(s) that control the mid-late G1 phase downregulation of p21cip1 by the extracellular matrix.
Integrated Growth Factor and ECM-dependent Signaling and Its Consequence for Cyclin D1, p21cip1, and Cell Cycle Progression through G1 Phase
While others have shown that sustained ERK activation is required for cell cycle progression, our results indicate that transient ERK activation is not without effect. Rather, we propose that transient ERK activity results in the induction of p21cip1 while sustained ERK activity, mediated by growth factor/ECM cooperation, and results in the induction of cyclin D1 (Fig. 9). The induction of p21cip1 and cyclin D1 are both important for the assembly of cyclin D–cdk4/6 complexes (LaBaer et al. 1997; Cheng et al. 1999). In addition, p21cip1 inhibits cyclin E–cdk2; our results indicate that full downregulation of p21cip1 gene expression requires cell adhesion to ECM and that this effect contributes to the control of cyclin E–cdk2 activity.
|
| Acknowledgments |
|---|
This research was supported by a grant from the National Cancer Institute (CA72639). M.E. Bottazzi has been supported by a post-doctoral fellowship from the Department of the Army.
Submitted: 6 May 1999
Revised: 22 July 1999
Accepted: 23 July 1999
1.used in this paper: cdk, cyclin-dependent kinase; CKI, cyclin-dependent kinase inhibitor; ECM, extracellular matrix; MEF, mouse embryo fibroblast; pRb, retinoblastoma protein; RTK, receptor tyrosine kinase
| References |
|---|
|
|
|---|
Albanese C., Johnson J., Watanabe G., Eklund N., Vu D., Arnold A. & Pestell R.G.. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions, J. Biol. Chem., 270, 1995, 23589–23597.
Aplin A.E. & Juliano R.L.. Integrin and cytoskeletal regulation of growth factor signaling to the MAP kinase pathway, J. Cell Sci., 112, 1999, 695–706.[Abstract]
Assoian R.K.. Anchorage-dependent cell cycle progression, J. Cell Biol., 136, 1997, 1–4.
Auer K.L., Park J.-S., Seth P., Coffey R.J., Darlingtons G., Abo A., McMahon M., DePinho R.A., Fisher P.B. & Dent P.. Prolonged activation of the mitogen-activated protein kinase pathway promotes DNA synthesis in primary hepatocytes from p21cip1/waf1-null mice, but not in hepatocytes from p16INK4a-null mice, Biochem. J., 336, 1998, 551–560.[Medline]
Böhmer R.M., Scharf E. & Assoian R.K.. Cytoskeletal integrity is required throughout the mitogen stimulation phase of the cell cycle and mediates the anchorage-dependent expression of cyclin D1, Mol. Biol. Cell., 7, 1996, 101–111.[Abstract]
Bosch M., Gil J., Bachs O. & Agell N.. Calmodulin inhibitor W13 induces sustained activation of ERK2 and expression of p21cip1, J. Biol. Chem., 273, 1998, 22145–22150.
Brugarolas J., Bronson R.T. & Jacks T.. p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells, J. Cell Biol., 141, 1998, 503–514.
Cheng M., Sexl V., Sherr C.J. & Rousell M.. Assembly of cyclin D-dependent kinase and titration of p27kip1 regulated by mitogen-activated protein kinase kinase (MEK1), Proc. Natl. Acad. Sci. USA, 95, 1998, 1091–1096.
Cheng M., Olivier P., Diehl J.A., Fero M., Roussel M.F., Roberts J.M. & Sherr C.J.. The p21Cip1 and p27Kip1 CDK inhibitors are essential activators of cyclin D-dependent kinases in murine fibroblasts, EMBO (Eur. Mol. Biol. Organ.) J., 18, 1999, 1571–1583.[Medline]
Clark E.A., King W.G., Brugge J.S., Symons M. & Hynes R.O.. Integrin-mediated signals regulated by members of the rho family of GTPases, J. Cell Biol., 142, 1996, 573–586.[Medline]
Day M.L., Foster R.G., Day K.C., Zhao X., Humphrey P., Swanson P., Postigo A.A., Zhang S.H. & Dean D.C.. Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor/E2F pathway, J. Biol. Chem., 272, 1997, 8125–8128.
El-Deiry W., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W. & Vogelstein B.. WAF1, a potential mediator of p53 tumor suppression, Cell, 75, 1993, 817–825.[Medline]
Fang F., Orend G., Watanabe N., Hunter T. & Ruoslahti E.. Dependence of cyclin E–cdk2 kinase activity on cell anchorage, Science., 271, 1996, 499–502.[Abstract]
Favata M.F., Horiuchi K.Y., Manos E.J., Daulerio A.J., Stradley D.A., Feeser W.S., Van Dyck D.E., Pitts W.J., Earl R.A. & Hobbs F.. Identification of a novel inhibitor of mitogen-activated protein kinase kinase, J. Biol. Chem., 273, 1998, 18623–18632.
Giancotti F.G.. Integrin signalingspecificity and control of cell survival and cell cycle progression, Curr. Opin. Cell Biol., 9, 1997, 691–700.[Medline]
Hengst L. & Reed S.I.. Translational control of p27kip1 accumulation during the cell cycle, Science, 271, 1996, 1861–1864.[Abstract]
Howe A., Aplin A.E., Alahari S.K. & Juliano R.L.. Integrin signaling and cell growth control, Curr. Opin. Cell Biol., 10, 1998, 220–231.[Medline]
Hunter T. & Pines J.. Cyclins and cancer IIcyclin D and CDK inhibitors come of age, Cell., 79, 1994, 573–582.[Medline]
Kerkhoff E. & Rapp U.R.. High-intensity raf signals convert mitotic cell cycling into cellular growth, Cancer Res., 58, 1998, 1636–1640.
LaBaer J., Garrett M.D., Stevenson L.F., Slingerland J.M., Sandhu C., Chou H.S., Fattaey A. & Harlow E.. New functional activities for the p21 family of CDK inhibitors, Genes Dev., 11, 1997, 847–862.
Lavoie J.N., L'Allemain G.L., Brunet A., Müller R. & Pouysségur J.. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway, J. Biol. Chem., 271, 1996, 20608–20616.
Li Y., Jenkins C.W., Nichols M.A. & Xiong Y.. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21, Oncogene, 9, 1994, 2261–2268.[Medline]
Lin T.H., Chen O., Howe A. & Juliano R.L.. Cell anchorage permits efficient signal transduction between Ras and its downstream kinases, J. Biol. Chem., 272, 1997, 8849–8852.
Liu Y., Martindale J.L., Gorospe M. & Holbrook N.J.. Regulation of p21waf1/cip1 expression through mitogen-activated protein kinase signaling pathway, Cancer Res., 56, 1996, 31–35.
Lloyd A.C., Obermüller F., Staddon S., Barth C.F., McMahon M. & Land H.. Cooperating oncogenes converge to regulate cyclin/cdk complexes, Genes Dev., 11, 1997, 663–677.
Lukas J., Bartkova J., Rohde M., Strauss M. & Bartek J.. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity, Mol. Cell Biol., 15, 1995, 2600–2611.[Abstract]
Macleod K.F., Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., Vogelstein B. & Jacks T.. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage, Genes Dev., 9, 1995, 935–944.
Miyamoto S., Teramoto H., Gutkind J.S. & Yamada K.M.. Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activationroles of integrin aggregation and occupancy of receptors, J. Cell Biol., 135, 1996, 1633–1642.
Montagnoli A., Fiore F., Eytan E., Carrano A.C., Draetta G.F., Hershko A. & Pagano M.. Ubiquitination of p27 is regulated by cdk-dependent phosphorylation and trimeric complex formation, Genes Dev., 13, 1999, 1181–1189.
Olson M.F., Paterson H.F. & Marshall C.J.. Signals from ras and rho GTPases interact to regulate expression of p21 Waf1/Cip1, Nature, 394, 1998, 295–299.[Medline]
Price D.J., Grove J.R., Calvo V., Avruch J. & Bierer B.E.. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase, Science, 257, 1992, 973–977.
Pumiglia K.M. & Decker S.T.. Cell cycle arrest mediated by the MEK/ mitogen-activated protein kinase pathway, Proc. Natl. Acad. Sci. USA., 94, 1997, 448–452.
Radeva G., Petrocelli T., Behrend E., Leung-Hagesteijn C., Filmus J., Slingerland J. & Dedhar S.. Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression, J. Biol. Chem, 272, 1997, 13937–13944.
Renshaw M.W., Ren X.-D. & Schwartz M.A.. Growth factor activation of MAP kinase requires cell adhesion, EMBO (Eur. Mol. Biol. Organ.) J., 18, 1997, 5592–5599.
Resnitzky D.. Ectopic expression of cyclin D1 but not cyclin E induces anchorage-independent cell cycle progression, Mol. Cell Biol., 17, 1997, 5640–5647.[Abstract]
Rishi A.K., Hsu C.K.A., Li X.-S., Hussain A., Gerald T.M. & Fontana J.A.. Transcriptional repression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 gene mediated by cis elements present in the 3'-untranslated region, Cancer Res., 57, 1997, 5129–5136.
Roovers K., Davey G., Zhu X., Bottazzi M.E. & Assoian R.K..
5β1 integrin controls cyclin D1 expression by sustaining MAP kinase activity in growth factor-treated cells, Mol. Biol. Cell, In press, 1999.
Sheaff R.J., Groudine M., Gordon M., Roberts J.M. & Clurman B.E.. Cyclin E–cdk2 is a regulator of p27kip1, Genes Dev., 11, 1997, 1464–1478.
Schulze A., Thome-Zerfass K., Bergès J., Middendorp S., Jansen-Dürr P. & Henglein B.. Anchorage-dependent transcription of the cyclin A gene, Mol. Cell. Biol., 16, 1996, 4632–4638.[Abstract]
Schwartz M.A., Lechene C. & Ingber D.E.. Insoluble fibronectin activates the Na/H antiporter by clustering and immobilizing integrin
5β1, independent of cell shape, Proc. Natl. Acad. Sci. USA., 88, 1991, 7849–7853.
Sewing A., Wiseman B., Lloyd A.C. & Land H.. High-intensity raf signal causes cell cycle arrest mediated by p21cip1, Mol. Cell. Biol., 17, 1997, 5588–5597.[Abstract]
Sherr C.J.. G1 phase progressioncycling on cue, Cell., 79, 1994, 551–555.[Medline]
Sherr C.J. & Roberts J.R.. Inhibitors of mammalian cyclin-dependent kinases, Genes Dev., 9, 1995, 1149–1163.
Short S.M., Talbott G.A. & Juliano R.L.. Integrin-mediated signaling events in human endothelial cells, Mol. Biol. Cell., 9, 1998, 1969–1980.
Vlahos C.J., Matter W.F., Hui K.Y. & Brown R.F.. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002), J. Biol. Chem, 269, 1994, 5241–5248.
Weber J.D., Raben D.M., Phillips P.J. & Baldassare J.J.. Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase, Biochem. J., 326, 1997, 61–68.[Medline]
Weinberg R.. The retinoblastoma protein and cell cycle control, Cell., 81, 1995, 323–330.[Medline]
Woods D., Parry D., Cherwinski H., Bosch E., Lees E. & McMahon M.. Raf-induced proliferation or cell cycle arrest is determined by the level of raf activity with arrest mediated by p21Cip1, Mol. Cell. Biol., 17, 1997, 5598–5611.[Abstract]
Zeng Y.X. & El-Diery W.S.. Regulation of p21 WAF1/CIP1 expression by the p53-independent pathways, Oncogene, 12, 1996, 1557–1564.[Medline]
Zhu X. & Assoian R.K.. Integrin-dependent activation of MAP kinasea link to shape-dependent cell proliferation, Mol. Biol. Cell., 6, 1995, 273–282.[Abstract]
Zhu X., Ohtsubo M., Böhmer R.M., Roberts J.M. & Assoian R.K.. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E–cdk2, and phosphorylation of the retinoblastoma protein, J. Cell Biol., 133, 1996, 391–403.
Zhu X., Roovers K., Davey G. & Assoian R.K.. Methods for analysis of adhesion-dependent cell cycle progression, Guan J.-L.. Signaling Through Cell Adhesion Molecules, 1999, 129–140, CRC Press, Boca Raton, FL.
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|